The estimated Net Worth of Matthew L Sherman is at least $18.1 Million dollars as of 15 February 2024. Matthew Sherman owns over 2,615 units of Deciphera Pharmaceuticals Inc stock worth over $2,782,631 and over the last 11 years he sold DCPH stock worth over $10,128,858. In addition, he makes $5,138,520 as Executive Vice President and Chief Medical Officer at Deciphera Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Matthew Sherman DCPH stock SEC Form 4 insiders trading
Matthew has made over 59 trades of the Deciphera Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 2,615 units of DCPH stock worth $40,846 on 15 February 2024.
The largest trade he's ever made was selling 26,000 units of Deciphera Pharmaceuticals Inc stock on 1 July 2016 worth over $903,240. On average, Matthew trades about 5,178 units every 44 days since 2013. As of 15 February 2024 he still owns at least 108,739 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Matthew Sherman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Matthew Sherman biography
Dr. Matthew L. Sherman M.D. serves as Executive Vice President, Chief Medical Officer of the Company. Dr. Sherman has served as our Executive Vice President, Chief Medical Officer since October 2019, and provided consulting services to us from January 2019 to October 2019. Dr. Sherman brings over 25 years of experience as a physician-scientist in clinical drug development in oncology and hematology at leading biotechnology and pharmaceutical companies. From 2006 to 2018, Dr. Sherman served as Chief Medical Officer of Acceleron Pharma, Inc., where he led medical research, clinical operations, biostatistics, data management, clinical pharmacology, medical writing, outsourcing and pharmacovigilance. Before joining Acceleron, Dr. Sherman was Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals (now Madrigal Pharmaceuticals). Prior to Synta, Dr. Sherman spent over a decade at Wyeth-Ayerst Research/Genetics Institute, where he led the successful submission, positive Oncologic Drug Advisory Committee recommendation, and FDA approval for the first antibody immune-drug conjugate for acute myeloid leukemia. He has published 260 original papers, book chapters, reviews and abstracts, and is listed as an inventor on 13 patents. He currently serves as a director of Pieris Pharmaceuticals. He also serves on the Geisel School of Medicine at Dartmouth Board of Advisors and Alumni Council. Dr. Sherman received a S.B. in Chemistry from the Massachusetts Institute of Technology and a M.D. from Dartmouth Medical School. He completed his internal medicine residency at Georgetown University Medical Center and fellowship in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Sherman is board certified in Internal Medicine and Medical Oncology and has held various academic and teaching positions at Harvard Medical School with corresponding clinical appointments at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston.
What is the salary of Matthew Sherman?
As the Executive Vice President and Chief Medical Officer of Deciphera Pharmaceuticals Inc, the total compensation of Matthew Sherman at Deciphera Pharmaceuticals Inc is $5,138,520. There are 2 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.
How old is Matthew Sherman?
Matthew Sherman is 64, he's been the Executive Vice President and Chief Medical Officer of Deciphera Pharmaceuticals Inc since 2019. There are 8 older and 12 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
What's Matthew Sherman's mailing address?
Matthew's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Insiders trading at Deciphera Pharmaceuticals Inc
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar, and Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
What does Deciphera Pharmaceuticals Inc do?
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
What does Deciphera Pharmaceuticals Inc's logo look like?
Complete history of Matthew Sherman stock trades at Acceleron Pharma Inc, Pieris Pharmaceuticals Inc, Pulmatrix Inc, and Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals Inc executives and stock owners
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Steven Hoerter,
President, Chief Executive Officer, Director -
Michael Taylor,
Director -
Matthew Sherman,
Executive Vice President, Chief Medical Officer -
Thomas Kelly,
Chief Financial Officer, Executive Vice President, Treasurer -
Steven L. Hoerter,
Pres, CEO & Director -
Daniel Flynn,
Founder, Executive Vice President, Chief Scientific Officer -
Dr. Matthew L. Sherman,
Exec. VP & Chief Medical Officer -
Ron Squarer,
Independent Director -
Frank Friedman,
Independent Director -
Thomas Patrick Kelly J.D.,
Exec. VP, CFO & Treasurer -
Dr. Matthew L. Sherman M.D.,
Exec. VP & Chief Medical Officer -
Dr. Daniel L. Flynn,
Exec. VP, Chief Scientific Officer & Founder -
Daniel C. Martin,
Sr. VP & Chief Commercial Officer -
Dr. Stephen B. Ruddy Ph.D.,
Sr. VP & Chief Technical Officer -
Susan Kelley,
Independent Director -
James Bristol,
Independent Chairman of the Board -
Edward Benz,
Independent Director -
Patricia Allen,
Independent Director -
Dennis Walsh,
Independent Director -
John Martin,
Independent Director -
Melissa Forst,
IR Contact Officer -
Lisa Amaya Price,
Sr. VP & Chief HR Officer -
Jennifer Larson,
Sr. VP of Fin. & Investor Relations -
Margarida Duarte,
Sr. VP & Head of International -
Jama Pitman,
Sr. VP of Regulatory, Quality & Portfolio Management -
Jeffrey M. Held J.D.,
Sr. VP & Gen. Counsel -
Jennifer Robinson,
VP of Investor Relations -
Dashyant Dhanak,
EVP & Chief Scientific Officer -
Leaf Venture Management Iii...,
-
Liam Ratcliffe,
Director -
Associates Llc Brightstar,
10% owner -
Christopher John Morl,
Chief Business Officer -
Michael Jay Ross,
Director -
Oliver Rosen,
Chief Medical Officer -
Stephen B. Ruddy,
Chief Technical Officer -
Daniel C. Martin,
Chief Commercial Officer -
Jama Pitman,
SVP, Chief Development Officer